Dr. Poe is the Head of CMC at Astrocyte Pharmaceuticals. He has >30 years of experience in the pharmaceutical industry with 14 years of CMC experience at Pfizer. Significant roles included leading the early phase CMC teams for 65 assets in neuropharmacology, cardiovascular and metabolic disease and dermatology. Additionally, while at Pfizer, he managed the Stability and Release Group which conducted cGMP stability testing on investigational API and drug products and release testing for cGMP radio-labeled clinical API used in ADME studies. He was the lead analyst for the API and drug product responsible for the successful NDA CMC submission for Geodon IM, a technically complex parenteral product with a novel proprietary modified β cyclodextrin excipient.
Dr. Poe is the managing member of Birch Biopharmaceutical Consultants since 2009 providing services for biopharmaceutical clients in early phase development and IND submissions, vendor management, late phase initial NDA filings, multivariate optimization and chemometrics. He currently serves on the advisory board for Molecular Isotope Technologies and Nature’s Fingerprint™, a pharmaceutical technology company using stable label isotopes for product and process authentication and infringement. He served on the scientific advisory board for Livwel Therapeutics with a developmental candidate in the area of asthma and uveitis. His research interests include analytical chemistry, experimental design, applied statistics and chemometrics.